Vutrisiran

Novartis has signed an up to $5.2 billion licensing and options deal with China-based Argo Biopharmaceutical for experimental cardiovascular drugs using RNA interference technology.

Novo Nordisk announced plans to initiate Phase 3 trials for coramitug, a potential first-in-class amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy, following successful completion of a Phase 2 study.

Transthyretin amyloid cardiomyopathy (ATTR-CM) has evolved from an untreatable condition to one managed with three FDA-approved disease-modifying agents: tafamidis, acoramidis, and vutrisiran.

• The FDA has approved Alnylam Pharmaceuticals' AMVUTTRA (vutrisiran) for treating cardiomyopathy in adults with wild-type or hereditary transthyretin-mediated amyloidosis, designed to reduce cardiovascular mortality and hospitalizations. • Following the approval, multiple financial institutions including Citi, Bank of America, Wells Fargo, and RBC Capital raised their price targets for Alnylam, with Citi analysts suggesting the drug is "on track to achieving mega blockbuster status." • Alnylam's stock surged 10.86% on the news, with trading volume reaching 1.8 million shares compared to the three-month daily average of 717,000, building on its impressive 19.23% year-to-date and 91.65% 52-week gains.

• Alnylam Pharmaceuticals has received FDA approval for Amvuttra (vutrisiran) to treat ATTR cardiomyopathy (ATTR-CM), significantly expanding the drug's addressable patient population beyond its original polyneuropathy indication. • The approval represents a major advancement in treatment options for ATTR-CM patients, a progressive and often fatal condition characterized by the buildup of abnormal amyloid protein in the heart muscle. • This expanded indication strengthens Alnylam's position in the ATTR treatment market, potentially increasing the company's revenue stream while providing patients with a new therapeutic option for managing cardiac manifestations of the disease.